Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

FCE-28068

Known as: FCE28068 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
PurposeIntravenously (i.v.) administered nanomedicines have the potential for tumour targeting due to the enhanced permeability… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
Review
2009
Review
2009
  • B. Říhová
  • Advanced drug delivery reviews
  • 2009
  • Corpus ID: 20423172
This paper reviews an early clinical experience with anthracycline (epirubicin; Epi or doxorubicin; Dox) containing an N-(2… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Recently we have described an HPMA copolymer conjugate carrying both the aromatase inhibitor aminoglutethimide (AGM) and… Expand
Is this relevant?
2007
2007
Our past research developed two N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (Dox) conjugates that became the… Expand
Is this relevant?
Review
2005
Review
2005
The last decade has seen successful clinical application of polymer-protein conjugates (e.g. Oncaspar, Neulasta) and promising… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
There are now at least seven polymer-drug conjugates that have entered phase I/II clinical trial as anticancer agents. These… Expand
  • figure 1
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?